Abstract | PURPOSE: The aim of this paper is to present the early phase of treating exudative age-releted macular degeneration (AMD)--coexisting witch vitreoretinal pathology--with combined pharmacological-surgical therapy. MATERIAL AND METHODS: Our observation is based on one clinical case of combined therapy: pars planavitrectomy (PPV) and one intravitrealranibizumab injection. Observation is being carried on larger patient group according to the treatment scheme presented In this paper. RESULTS: In this case described combined pharmacological-surgical therapy allowed a significant improvement in visual acuity and closure of choroidal neovascularization (CNV), leakage confirmed by fluorescein angiography (FA) and optical coherence tomography (AMD). The treatment is being continued--another ranibizumab injection according to PRONTO study reinjection criteria. CONCLUSIONS: The pathomechanism of exudative AMD and coexistance of vitreoretinal pathology implications confirm reasonability of combined therapy.Due to actual clinical studies: the pharmacological -surgical treatment reduces the number of required intravitreal anti- VEGF agents injections. To confirm this observation we need to perform large randomised clinical studies.
|
Authors | Małgorzata Figurska, Jacek Robaszkiewicz, Agnieszka Bogdan-Bandurska |
Journal | Klinika oczna
(Klin Oczna)
Vol. 113
Issue 1-3
Pg. 56-9
( 2011)
ISSN: 0023-2157 [Print] Poland |
Vernacular Title | Terapia łaczona chirurgiczno-farmakologiczna wysiekowej postaci zwyrodnienia plamki zawiazanego z wiekiem. |
PMID | 21853953
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Ranibizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(administration & dosage)
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Combined Modality Therapy
- Exudates and Transudates
- Female
- Fluorescein Angiography
- Humans
- Intravitreal Injections
- Macular Degeneration
(drug therapy, surgery)
- Ranibizumab
- Treatment Outcome
- Vitrectomy
(methods)
- Vitreous Body
(surgery)
|